Progenity Announces Poster Presentations at Digestive Disease Week 2021
Two Abstracts Support Company’s Targeted Therapeutics Program including the Drug Delivery System
May 24, 2021 07:30 ET | Source: Progenity, Inc. Progenity, Inc. San Diego, California, UNITED STATES
SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the presentation of two posters related to the company’s Targeted Therapeutics program presented at the 2021 Digestive Disease Week® (DDW) Virtual Event. The posters include a preclinical study evaluating treatment of intestinal inflammation with the Company’s PGN-600 (liquid tofacitinib) product candidate and a second preclinical study of its investigational ingestible Drug Delivery System (DDS). DDW is the world’s premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy